GlucoTrack Stock Soars 117% on Positive Clinical Trial Results
The biotech firm's implantable glucose monitor demonstrated high accuracy in its first-in-human study, signaling a potential market disruption.
Shares of GlucoTrack, Inc. (GCTK) skyrocketed over 117% in recent trading, accompanied by a massive surge in volume 72 times the daily average. The rally was ignited after the company announced for its long-term, implantable Continuous Blood Glucose Monitor (CBGM).
The study's success marks a significant milestone for GlucoTrack and a potential leap forward in diabetes technology. Unlike conventional monitors that measure glucose in interstitial fluid, GlucoTrack's device directly measures glucose from the blood. This approach is designed to eliminate the lag time that can be critical for diabetes management. The implantable sensor is intended for three years of continuous use without an external wearable component, a key differentiator in the market.
The clinical trial, conducted with 10 patients with Type 1 or Type 2 diabetes, yielded impressive results. The CBGM achieved a Mean Absolute Relative Difference (MARD) of 7.7 percent, a key metric of accuracy that is highly competitive with leading systems currently on the market. The device also demonstrated a 99 percent data capture rate with no serious adverse events reported, .
Investors reacted with strong optimism to the news, seeing the device as a potential disruptor in the multi-billion dollar glucose monitoring industry. The successful trial moves the company one step closer to challenging established players with a next-generation, patient-centric solution.
GlucoTrack is not resting on these results. The company plans to build on this momentum by initiating a to further evaluate the safety and durability of the device. While the CBGM is still an investigational device and awaits regulatory approval, this successful human trial is a critical validation of GlucoTrack's technology and a key catalyst for the company's future.